Saturday 17 October 2026
Export ARWR’s income statement to Excel — free account
Arrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024. In the quarter to June 2026, revenue grew 171.0%, EPS fell 7.94%, free cash flow fell 15.4% and total debt rose 259.5%, each against the same quarter a year earlier.
55.90
2.60
−4.44%
Follow ARWR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 43.39 | 0.00 |
+8 more quarters Free account |
P/S ratio |
17.46 | 14.36 | 8.34 | 5.56 | |
P/FCF ratio |
0.00 | 0.00 | 28.25 | 29.41 | |
P/Operating CF |
(65.85) | 105.75 | 674.88 | 225.14 | |
P/B ratio |
25.08 | 14.91 | 16.17 | 9.16 | |
Price to Tangible BV |
25.38 | 15.06 | 16.36 | 9.29 | |
EV/Sales |
16.35 | 12.91 | 7.69 | 4.76 | |
EV/EBITDA |
0.00 | 0.00 | 26.21 | 33.90 | |
EV/Operating CF |
(185.40) | (221.09) | 24.71 | 21.99 | |
EV/FCF |
(145.77) | (157.79) | 26.04 | 25.17 | |
Quick Ratio |
5.68 | 6.10 | 3.27 | 4.74 | |
Current Ratio |
5.90 | 6.23 | 3.38 | 4.86 | |
Net Debt/EBITDA |
4.49 | 6.60 | (15.12) | (13.49) | |
Debt/Assets |
40.91% | 38.87% | 12.66% | 18.40% | |
Debt/Equity |
1.85 | 1.47 | 0.36 | 0.51 | |
Asset Turnover |
0.38 | 0.32 | 0.83 | 0.66 | |
Operating CF/Net income |
0.91 | (0.64) | 0.44 | (0.86) | |
Capex/Depreciation |
(0.66) | (0.57) | (0.34) | (1.46) | |
Interest Coverage |
(6.92) | (5.92) | 1.81 | 2.03 | |
Research and Development Expense of Revenue |
263.41% | 234.96% | 67.11% | 68.11% | |
Selling, General and Administrative Expense of Revenue |
62.62% | 56.61% | 17.43% | 14.69% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
19.76% | 22.61% | 7.34% | 7.44% | |
Graham Net Nets |
0.00 | 0.02 | 0.01 | 0.01 | |
Graham Number |
0.00 | 0.00 | 11.89 | 0.00 | |
Earnings Yield |
(2.76%) | (3.43%) | 2.30% | (0.23%) | |
Free Cash Flow Yield |
(0.64%) | (0.57%) | 3.54% | 3.40% | |
Revenue per Share |
0.52 | 0.52 | 1.93 | 1.92 | |
Operating CF per Share |
(1.24) | 0.59 | 0.10 | 0.15 | |
Capex per Share |
(0.03) | (0.02) | (0.02) | (0.06) | |
Free Cash Flow per Share |
(1.26) | 0.57 | 0.08 | 0.10 | |
Cash per Share |
11.17 | 12.53 | 6.69 | 6.87 | |
Shareholders Equity per Share |
3.25 | 4.21 | 4.11 | 3.76 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.25 | 4.21 | 4.11 | 3.76 | |
Free Cash Flow |
(181.32) | 81.88 | 11.33 | 13.00 | |
Working Capital |
1,388.07 | 1,544.53 | 826.96 | 755.15 | |
Capital Expenditures |
(3.85) | (2.56) | (2.15) | (7.49) | |
Net Current Asset Value |
25.44 | 170.40 | 132.91 | 68.76 | |
EV/EBIT |
0.00 | 0.00 | 27.90 | 40.15 | |
Capex to Sales |
0.05 | 0.03 | 0.01 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 30.27 | 46.91 | |
| Other line items | |||||
Average Receivables |
9.13 | 9.03 | 110.69 | 4.04 | |
Average Payables |
30.41 | 20.36 | 23.70 | 14.53 | |
Average Assets |
1,746.31 | 1,920.88 | 1,308.94 | 1,262.55 | |
Average Common Equity |
492.92 | 641.57 | 309.39 | 347.24 |
Columns are period end dates